Carcinogenicity of biopharmaceuticals

Genotoxicity and Carcinogenicity Testing of Pharmaceuticals

Volumn , Issue , 2015, Pages 125-157

  Dempster, Maggie ^a   Siezen, Kris ^b   Braak, Baster ^c   van den Brink, Willem ^c   Emerenciana, Annette ^c   Bellanti, Francesco ^c   Duijnhoven, Ruben G ^b,d   Kwa, Marcel ^b   van der Laan, Jan Willem ^b,c,e  

^a GLAXOSMITHKLINE   (United States)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Biotechnology derived pharmaceuticals; Carcinogenicity evaluation; GLP 1 agonists; Immunomodulators; Insulin; Non clinical evaluation

Indexed keywords

EID: 84979255475     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-22084-0_8     Document Type: Chapter

References (132)

1. International Conference on Harmonisation. ICH Guideline S1A: Need for Carcinogenicity Studies of Pharmaceuticals. November 1995. http://www.ich.org/fi leadmin/Public_Web_ Site/ICH_Products/Guidelines/Safety/S1A/Step4/S1A_Guideline.pdf. Accessed 23 Dec 2014.
2. Van Oosterhout JP, Van der Laan JW, De Waal EJ, Olejniczak K, Hilgenfeld M, Schmidt V, Bass R (1997) The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul Toxicol Pharmacol 25(1):6-17.
3. Bronchud MH (2007) Molecular oncology. In: Meyers RA (ed) Cancer. From mechanisms to therapeutic approaches. Wiley-VCH Verlag, Weinheim, pp 3-54.
4. Maher ER, Neumann HPH, Richard S (2011) von Hippel-Lindau disease: a clinical and scientifi c review. Eur J Hum Genet 19(6):617-623. doi: 10.1038/ejhg.2010.175, Epub 2011 Mar 9.
5. Somasundaram A, Ardanowski N, Opalak CF, Fillmore HL, Chidambaram A, Broaddus WC (2014) Wilms tumor 1 gene, CD97, and the emerging biogenetic profile of glioblastoma. Neurosurg Focus 37(6):E14. doi: 10.3171/2014.9.FOCUS14506.
6. Kinzler KW, Vogelstein B (1997) Gatekeepers and caretakers. Nature 386:761-763. doi: 10.1038/386761a0.
7. DeVries A, Van Oostrom CTM, Hofhuis FMA, Dortant PM, Berg RJW, DeGruijl FR, Wester PW, VanKreijl CF, Capel PJA, VanSteeg H, Verbeek SJ (1995) Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature 77:169-173. doi: 10.1038/377169a0.
8. Melis JPM, Wijnhoven SW, Beems RB, Roodbergen M, vanden Berg J, Moon H, Friedberg E, van der Horst GTJ, Hoeijmakers JHJ, Vijg J, van Steeg H (2008) Mouse models for Xeroderma pigmentosum group A and group C show divergent cancer phenotypes. Cancer Res 68(5):1347-1353. doi: 10.1158/0008-5472.CAN-07-6067.
9. Robinson DE, MacDonald JS (2001) Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute. Toxicol Pathol 29(Suppl):13-19.
10. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CAJ, Butel JS, Bradley A (1992) Mice deficient for p53 are developmental normal but susceptible to spontaneous tumors. Nature 355(6366):215-221.
11. Hanahan D, Weinberg RA (2011) 2011 Hallmarks of cancer: the next generation. Cell 144(5):646-674. doi: 10.1016/j.cell.2011.02.013.
12. Tischler AS, Powers JF, Pignatello M, Tsokas P, Downing JC, McClain RM (1999) Vitamin D3-induced proliferative lesions in the rat adrenal medulla. Toxicol Sci 51(1):9-18.
13. Silva Lima B, Van der Laan JW (2000) Mechanisms of nongenotoxic carcinogenesis and assessment of the human hazard. Regul Toxicol Pharmacol 32(2):135-143. doi: 10.1006/ rtph.2000.1427.
14. Bronchud MH (2002) Is cancer really a 'local' cellular clonal disease? Med Hypotheses 59(5):560-565.
15. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339(6127):1546-1558. doi: 10.1126/science.1235122.
16. Pan Z-Z, Godwin AK (2007) Oncogenes. In: Meyers RA (ed) Cancer. From mechanisms to therapeutic approaches. Wiley-VCH Verlag, Weinheim, pp 55-114.
17. EMA EPAR Kepivance 2005. http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Scientifi c_Discussion/human/000609/WC500040536.pdf.
18. Sterner E, Meli L, Kwon SJ, Dordick JS, Linhardt RJ (2013) FGF-FGFR signaling mediated through glycosaminoglycans in microtiter plate and cell-based microarray platforms. Biochemistry 52(50):9009-9019. doi: 10.1021/bi401284r.
19. International Conference on Harmonisation. ICH Guideline S6(R1): Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. June 2011. http://www.ich.org/ fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_ Guideline.pdf. Accessed 23 Dec 2014.
20. Vahle JL, Finch GL, Heidel SM, Hovland DN Jr, Ivens I, Parker S, Ponce RA, Sachs C, Steigerwalt R, Short B, Todd MD (2010) Carcinogenicity assessments of biotechnologyderived pharmaceuticals: a review of approved molecules and best practice recommendations. Toxicol Pathol 38:522-553. doi: 10.1177/0192623310368984.
21. Bugelski PJ, Volk A, Walker MR, Krayer JH, Martin P, Descotes J (2010) Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to infl uence human neoplasia. Int J Toxicol 29(5):435-466. doi: 10.1177/1091581810374654.
22. International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. http://www.ich.org.
23. Terrell TG, Green JD (1994) Issues with biotechnology products in toxicologic pathology. Toxicol Pathol 22(2):187-193.
24. Inoue T (1998) Biotechnologically-derived pharmaceuticals in Japan: present and future prospects. In: Griffi ths SA, Lumley CE (eds) Safety evaluation of biotechnologically-derived pharmaceuticals: facilitating a scientifi c approach. Kluwer Academic Publishers, Dordrecht, pp 51-63.
25. Rosenblum IY, Dayan AD (2002) Carcinogenicity testing of IL-10: principles and practicalities. Hum Exp Toxicol 21(7):347-358.
26. Ning S, Shui C, Khan WB, Benson W, Lacey DL, Knox SJ (1998) Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. Int J Radiat Oncol Biol Phys 40(1):177-187.
27. FDA Kepivance, Prescribing information 2004, 2013. http://www.accessdata.fda.gov/drugsatfda_ docs/label/2013/125103s146lbl.pdf.
28. EMA EPAR Neorecormon (2004) http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Scientifi c_Discussion/human/000116/WC500024975.pdf.
29. FDA Epoietin Alfa, Prescribing information 1989. http://www.accessdata.fda.gov/drugsatfda_ docs/label/2013/103234s5323lbl.pdf.
30. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R (1999) Insulin receptor isoform A, a newly recognized, high-affi nity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19(5):3278-3288.
31. Taguchi A, White MF (2008) Insulin-like signaling, nutrient homeostasis, and life span. Annu Rev Physiol 70:191-212.
32. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12):915-928. doi: 10.1038/nrc2536.
33. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12(3):159-169. doi: 10.1038/nrc3215.
34. Malaguarnera R, Sacco A, Voci C, Pandini G, Vigneri R, Belfiore A (2012) Proinsulin binds with high affi nity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinology 153(5):2152-2163. doi: 10.1210/en.2011-1843, Epub 2012 Feb 21.
35. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129(7):1261-1274.
36. Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7:85-96.
37. Cheng Z, Tseng Y, White MF (2010) Insulin signaling meets mitochondria in metabolism. Trends Endocrinol Metab 21(10):589-598. doi: 10.1016/j.tem.2010.06.005, Epub 2010 Jul 16.
38. Schwartz GP, Burke GT, Katsoyannis PG (1989) A highly potent insulin: des-(B26-B30)-[AspB10, TyrB25-NH2]insulin(human). Proc Natl Acad Sci U S A 86(2):458-461.
39. Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R (1997) ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog 18(1):19-25.
40. Glendorf T, Knudsen L, Stidsen CE, Hansen BF, Hegelund AC, Sorensen AR, Nishimura E, Kjeldsen T (2012) Systematic evaluation of the metabolic to mitogenic potency ratio for B10-substituted insulin analogues. PLoS One 7:e29198.
41. Hansen BF, Kurtzhals P, Jensen AB, Dejgaard A, Russell-Jones D (2011) Insulin X10 revisited: a super-mitogenic insulin analogue. Diabetologia 54(9):2226-2231. doi: 10.1007/ s00125-011-2203-8, Epub 2011 Jun 3.
42. Gallagher EJ, Alikhani N, Tobin-Hess A, Blank J, Buffin NJ, Zelenko Z, Tennagels N, Werner U, LeRoith D (2013) Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor. Diabetes 62(10):3553-3560. doi: 10.2337/db13-0249, Epub 2013 Jul 8.
43. Ter Braak B, Siezen CL, Kannegieter N, Koedoot E, van de Water B, van der Laan JW (2014) Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel. Arch Toxicol 88(4):953-966. doi: 10.1007/s00204-014-1201-2, Epub 2014 Jan 25.
44. Sciacca L, Cassarino MF, Genua M, Vigneri P, Giovanna Pennisi M, Malandrino P, Squatrito S, Pezzino V, Vigneri R (2014) Biological effects of insulin and its analogs on cancer cells with different insulin family receptor expression. J Cell Physiol 229(11):1817-1821. doi: 10.1002/jcp.24635.
45. Oleksiewicz MB, Bonnesen C, Hegelund AC, Lundby A, Holm GM, Jensen MB, Krabbe JS (2011) Comparison of intracellular signalling by insulin and the hypermitogenic AspB10 analogue in MCF-7 breast adenocarcinoma cells. J Appl Toxicol 31(4):329-341. doi: 10.1002/ jat.1590, Epub 2010 Oct 8.
46. Dideriksen LH, Jørgensen LN, Drejer K (1992) Carcinogenic effect on female rats after 12 months administration of the insulin analogue B10 Asp. Diabetes 41:143A.
47. Tennagels N, Welte S, Hofmann M, Brenk P, Schmidt R, Werner U (2013) Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats [corrected]. Diabetologia 56(8):1826-1834. doi: 10.1007/s00125-013-2923-z, Epub 2013 May 8.
48. Ter Braak B, Siezen CLE, Speksnijder EN, Koedoot E, van Steeg H, Salvatori DCF, van de Water B, van der Laan JW (2015) Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/+WAPCre mouse model. Breast Cancer Res 17:14. doi: 10.1186/s13058-015-0518-y.
49. EMA (2001) Points to consider on the non-clinical assessment of the carcinogenic potential of human insulin analogues. http://www.ema.europa.eu/docs/en_GB/document_library/ Scientifi c_guideline/2009/09/WC500003252.pdf.
50. Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, Vigneri R (2010) Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 53(8):1743-1753. doi: 10.1007/s00125-010-1760-6, Epub 2010 Apr 28.
51. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49(6):999-1005.
52. Yehezkel E, Weinstein D, Simon M, Sarfstein R, Laron Z, Werner H (2010) Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor. Diabetologia 53(12):2667-2675. doi: 10.1007/ s00125-010-1899-1, Epub 2010 Sep 12.
53. Sommerfeld MR, Muller G, Tschank G, Seipke G, Habermann P, Kurrle R, Tennagels N (2010) In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One 5(3):e9540. doi: 10.1371/journal.pone.0009540.
54. Teng JA, Hou RL, Li DL, Yang RP, Qin J (2011) Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation. Horm Metab Res 43:519-523. doi: 10. 1055/s-0031-1280780, Epub 2011 Jul 19.
55. Kellerer M, Haring HU (2001) Insulin analogues: impact of cell model characteristics on results and conclusions regarding mitogenic properties. Exp Clin Endocrinol Diabetes 109(1):63-64.
56. Staiger K, Hennige AM, Staiger H, Haring HU, Kellerer M (2007) Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 39(1):65-67.
57. Pierre-Eugene C, Pagesy P, Nguyen TT, Neuille M, Tschank G, Tennagels N, Hampe C, Issad T (2012) Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2. PLoS One 7(7):e41992. doi: 10.1371/ journal.pone.0041992, Epub 2012 Jul 26.
58. Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G (2002) Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 21(3):171-179.
59. Stammberger I, Essermeant L (2012) Insulin glargine: a reevaluation of rodent carcinogenicity fi ndings. Int J Toxicol 31(2):137-142. doi: 10.1177/1091581811431111, Epub 2012 Jan 3.
60. Ter Braak SJ, Wink S, Koedoot E, Pont C, Siezen CLE, Van der Laan JW, van de Water B (2015) Alternative signaling network activation through different insulin receptor family members caused by promitogenic antidiabetic insulin analogues in human mammary epithelial cells. Breast Cancer Res 17:97. doi: 10.1186/s13058-015-0600-5.
61. EMA EPAR Byetta 2006. http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Scientifi c_Discussion/human/000698/WC500051842.pdf.
62. EMA EPAR Bydureon 2011. http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Public_assessment_report/human/002020/WC500108239.pdf.
63. EMA EPAR Victoza 2009. http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Public_assessment_report/human/001026/WC500050016.pdf.
64. EMA EPAR Lyxumia 2013. http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Public_assessment_report/human/002445/WC500140449.pdf.
65. EMA EPAR Trulicity 2014. http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Public_assessment_report/human/002825/WC500179473.pdf.
66. EMA EPAR Eperzan 2014. http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Public_assessment_report/human/002735/WC500165119.pdf.
67. Sheiner LB, Steimer JL (2000) Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40:67-95.
68. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G (2005) Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classifi cation of biomarkers. Pharm Res 22(9):1432-1437, Epub 2005 Aug 24.
69. Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA (2008) Mechanismbased pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 29(4):186-191. doi: 10.1016/j.tips.2008.01.007, Epub 2008 Mar 18.
70. Derendorf H, Meibohm B (1999) Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res 16(2):176-185.
71. Knudsen BL, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen SD, Moses AC, Mølck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M, Moerch U (2010) Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing clacitonin release and C-cell proliferation. Endocrinology 151(4):1473-1486. doi: 10.1210/en.2009-1272, Epub 2010 Mar 4.
72. Ponce RA, Gelzleichter T, Haggerty HG, Heidel S, Holdren MS, Lebrec H, Mellon RD, Pallardy M (2014) Immunmodulation and lymphoma in humans. J Immunotoxicol 11(1):1-12. doi: 10.3109/1547691X.2013.798388.
73. Salavoura K, Kolialexi A, Tsangaris G, Mavrou A (2008) Development of cancer in patients with primary immunodefi ciencies. Anticancer Res 28:1263-1269.
74. Weaver JL (2012) Establishing the carcinogenic risk of immunomodulatory drugs. Toxicol Pathol 40:267-271. doi: 10.1177/0192623311427711.
75. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F (2005) Carcinogenicity of human papillomaviruses. Lancet Oncol 6(4):204.
76. Gaschen L, Schuurman HJ (2001) Ultrasound detection of non-Hodgkin's lymphoma in three cynomolgus monkeys after renal transplantation and cyclosporine immunosuppression. J Med Primatol 30(2):88-93.
77. Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW (2006) Post-transplant de novo malignancies in renal transplant recipients: the past and present. Trans Internatl 19:607-620.
78. Dempster AM (2000) Nonclinical safety evaluation of biotechnologically derived pharmaceuticals. In: El-Gewely MR (ed) Biotechnology annual review. Elsevier Science, Amsterdam, pp 221-258.
79. Wordell CJ (1991) Biotechnology update. Hosp Pharm 26:897-900.
80. Goldstein G (1987) Overview of the development of orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation. Transplant Proc 19(2 Suppl 1):1-6.
81. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 323(25):1723-1728.
82. Macsween KF, Crawford DH (2003) Epstein-Barr virus-recent advances. Lancet Infect Dis 3:131-140.
83. Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4:757-768. doi: 10.1038/nrc1452.
84. Clarke J, Hurst C, Martin P, Vahle J, Ponce R, Mounho B, Heidel S, Andrews L, Reynolds T, Cavagnaro J (2008) Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate? Reg Toxicol Pharmacol 50:2-22. doi: 10.1016/j. yrtph.2007.08.001.
85. Bugelski PJ, Herzyk DJ, Rehm S, Harmsen AG, Gore EV, Williams DM, Maleeff BE, Badger AM, Truneh A, O'Brien SR, Macial RA, Wier PJ, Morgan DG, Hart TK (2000) Preclinical development of keliximab, a primatized™ anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Hum Exp Toxicol 19:230- doi: 10.1191/096032700678815783.
86. Strangfeld A, Zink A (2010) Are we playing it safe? Tumor necrosis factor alpha inhibition and the risk of solid malignancies. Rheumatologist 1-7. http://www.the-rheumatologist.org/ details/article/867933/Are_We_Playing_It_Safe.html.
87. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxininduced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72(9): 3666-3670.
88. Balkwill F (2009) Tumor necrosis factor and cancer. Nat Rev Cancer 9:361-371. doi: 10.1038/ nrc2628.
89. Raaschou P, Simard JF, Neovius M, Askling J (2011) Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specifi c cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum 63(7):1812-1822. doi: 10.1002/art.30247.
90. Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzock R, Thomas DA, Faderi S, Lerner S, O'Brien S, Albitar M (2002) The clinical signifi cance of tumor necrosis factor-a plasma level in patients having chronic lymphocytic leukemia. Blood 100(4):1215-1219.
91. Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, DeWitte M, Sturgeon C, Propper D, Balkwill FR, Smyth JF (2008) A clinical study assessing the tolerability and biological effects of infl iximab, a TNF-a inhibitor, in patients with advanced cancer. Ann Oncol 19:1340-1346. doi: 10.1093/annonc/ mdn054.
92. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ (1999) Tumor necrosis factor alpha antibody (infl iximab) therapy profoundly down-regulates the infl ammation in Crohn's ileocolitis. Gastroenterology 116(1):22-28.
93. FDA Etanercept, Summary basis of approval (1998) http://www.fda.gov/downloads/Drugs/ DevelopmentApprova l P r o c e s s / H owDrugsareDevelopedandApprove d / ApprovalApplications/TherapeuticBiologicApplications/ucm088697.pdf.
94. Raaschou P, Simard JF, Holmqvist M, Askling J (2013) Rheumatoid arthritis, anti-tumor necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 346:1-12. doi: 10.1136/bmj.f1939, Published 8 April 2013.
95. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275-2285. doi: 10.1001/jama.295.19.2275.
96. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ (2009) Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 68(7):1177- doi: 10.1136/ard.2008.094904.
97. Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis. The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50(6):1740-1751. doi: 10.1002/art.20311.
98. Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy. Analyses from a large US observational study. Arthritis Rheum 56(9):2886-2895. doi: 10.1002/art.22864.
99. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumor necrosis factor antagonists. Ann Rheum Dis 64:1421-1426. doi: 10.1136/ ard.2004.033993.
100. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L (2009) Cancer risk in patients with rheumatoid arthritis treated with antitumor necrosis factor a therapies: does the risk change with the time since start of treatment? Arthritis Rheum 60(11):3180-3189. doi: 10.1002/art.24941.
101. Haynes K, Beukelman T, Curtis JR, Newcomb C, Herrinton LJ, Graham DJ, Solomon DH, Griffin MR, Chen L, Liu L, Saag KG, Lewis JD (2013) Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune mediated diseases. Arthritis Rheum 65(1):48-58. doi: 10.1002/art.37740.
102. Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S (2006) Tumor necrosis factor a antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54(9):2757-2764.
103. Dreyer L, Mellemkjaer L, Andersen AR, Bennett P, Poulsen UE, Ellingsen TJ, Duijnhoven RG, Straus SM, Raine JM, de Boer A, Hoes AW, De Bruin ML (2013) Number of patients studied prior to approval of new medicines: a database analysis. PLoS Med 10(3):e1001407. doi: 10.1371/journal.pmed.1001407, Epub 2013 Mar 19.
104. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, Fulton S, Suarez-Almazor ME (2012) Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 308(9):898-908. doi: 10.1001/2012.jama.10857.
105. Strangfeld A, Hierse F, Rau R, Burmester G-R, Krummel-Lorenz B, Demary W, Listing J, Zink A (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12(1):R5. doi: 10.1186/ar2904, Epub 2010 Jan 8.
106. Dixon WG, Watson KD, Lunt M, Mercer LK, British Society for Rheumatology Biologics Register Control Centre Consortium, Hyrich KL, Symmons DPM (2010) Infl uence of antitumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res 62(6):755-763. doi: 10.1002/acr.20129.
107. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Grannath F, Catrina AI, Rosenquist R, Feltelius N, Sundström C, Klareskog L (2006) Association of chronic infl ammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54(3):692-701. doi: 10.1002/art.21675.
108. Hill AB (1965) The environment and disease: association or causation? Proc R Soc Med 58:295-300.
109. Stricker BH, Stijnen T (2010) Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol 25(4):245-251. doi: 10.1007/s10654-010-9451-7, Epub 2010 Apr 1.
110. WHO. http://www.who.int/medicines/areas/quality_safety/safety_effi cacy/pharmvigi/en/.
111. Miacalcin team Novartis Pharmaceuticals Corporation Available for Public Disclosure without Redaction Miacalcin® (calcitonin-salmon) FDA Joint Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee Meeting on the Benefi t/Risk of Salmon Calcitonin for the Treatment of Postmenopausal Osteoporosis -Briefi ng Book, 29 Jan 2013.
112. Chesnut CH III, Silverman SL, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the PROOF Study. Am J Med 109(4):267-276.
113. EMA EPAR Cimzia 2014. http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/ human/001037/WC500069736.pdf.
114. EMA EPAR Humira. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Procedural_steps_taken_and_scientifi c_information_after_authorisation/human/000481/ WC500050869.pdf.
115. EMA EPAR Remicade 2014. http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/ human/000240/WC500050890.pdf.
116. EMA EPAR Enbrel 2014. http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/ human/000262/WC500027366.pdf.
117. Raaschou P, Frisell T, Askling J (2014) TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 0:1-7. doi: 10.1136/annrheumdis-2014-205745.
118. EMA EPAR Aranesp 2006. http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/ human/000332/WC500026145.pdf.
119. EMA EPAR Somatropin referral 2011. http://www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/referrals/Somatropin/human_referral_000287.jsp&mid= WC0b01ac05805c516f.
120. Andersson C, Vaag A, Selmer C, Schmiegelow M, Sørensen R, Lindhardsen J, Gislason GH, Køber L, Torp-Pedersen C (2012) Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people. BMJ Open 2(3). pii: e000433. doi: 10.1136/ bmjopen-2011-000433. Print 2012.
121. Colhoun HM (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52(9):1755-1765. doi: 10.1007/s00125-009-1453-1, Epub 2009 Jul 15.
122. Currie CJ, Poole CD, Gale EA (2009) The infl uence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52(9):1766-1777. doi: 10.1007/s00125-009-1440-6, Epub 2009 Jul 2.
123. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, Sawicki PT (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52(9):1732-1744. doi: 10.1007/s00125-009-1418-4, Epub 2009 Jun 30.
124. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52(9):1745-1754. doi: 10.1007/s00125-009-1444-2, Epub 2009 Jul 9.
125. Kostev K (2012) Risk of breast cancer in patients on long-acting insulin analogues in comparison with those on human insulin. Diabetologia 55(5):1554-1555. doi: 10.1007/s00125-012-2497-1, Epub 2012 Feb 19.
126. Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, Lamanna C, Bracali I, Bigiarini M, Barchielli A, Marchionni N, Rotella CM (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33(9):1997-2003. doi: 10.2337/dc10-0476, Epub 2010 Jun 14.
127. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH (2012) Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 55(1):51-62. doi: 10.1007/s00125-011-2312-4, Epub 2011 Sep 29.
128. Home PD, Lagarenne P (2009) Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52(12):2499-2506. doi: 10.1007/ s00125-009-1530-5, Epub 2009 Sep15.
129. Rosenstock J, Fonseca V, McGill JB, Riddle M, Halle JP, Hramiak I, Johnston P, Davis M (2009) Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: fi ndings from a 5 year randomised, open-label study. Diabetologia 52(9):1971-1973. doi: 10.1007/s00125-009-1452-2, Epub 2009 Jul 16.
130. Nagel JM, Mansmann U, Wegscheider K, Rohmel J (2010) Insulin resistance and increased risk for malignant neoplasms: confounding of the data on insulin glargine. Diabetologia 53(1):206-208. doi: 10.1007/s00125-009-1535-0, Epub 2009 Sep 24.
131. Pocock SJ, Smeeth L (2009) Insulin glargine and malignancy: an unwarranted alarm. Lancet 374(9689):511-513. doi: 10.1016/S0140-6736(09)61307-6, Epub 2009 Jul 17.
132. Bronsveld H, ter Braak B, Karlstad Ø, Vestergaard P, Starup-Linde J, Bazelier MT, De Bruin ML, de Boer A, Siezen CLE, van de Water B, van der Laan JW, Schmidt MK (2015) Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Res 17(1):100. doi: 10.1186/s13058-015-0611-2.